BUDGET IMPACT OF SWITCHING FROM AN EXTENDED-RELEASE TO AN IMMEDIATE-RELEASE FORMULATION OF TACROLIMUS IN RENAL TRANSPLANT RECIPIENTS IN SPAIN

Author(s)

Sanz-Granda Á1, Ramos-Verde A2, Aguinaga-Barrilero A3, Rebollo-Laserna FJ3
1Proyectos de Farmacoeconomía, Navacerrada, Spain, 2Fundación Jiménez Díaz, Madrid, Spain, 3SANDOZ, Aravaca, Madrid, Spain

Presentation Documents

OBJECTIVES:  Conversion (1:1, mg:mg) from Advagraf® (extended-release tacrolimus [1dTAC], the most prescribed in Spain) to Adoport® (immediate-release tacrolimus [2dTAC]) shows that 2dTAC needed a lower dose 90 days later (4.9±2.9 vs

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PUK5

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Urinary/Kidney Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×